Мовасин Drug photo

The description is actual on 20.03.2015

  • Latin name: Movasin
  • ATH code: M01AC06
  • Active ingredient: Meloksikam (Meloxicam)
  • Producer: JSC Sintez (Russia)


1 tablet includes 7,5 or 15 mg of a meloksikam – active ingredient.

Additional ingredients: povidone, MKTs, lactose, krospovidon, potato starch, magnesium stearate.

1 ml of intramuscular solution includes 10 mg of a meloksikam – active ingredient.

Additional ingredients: half-oxameasures, glycine, glycofurfural, Megluminum, sodium chloride, sodium hydroxide, water for and.

Release form

Drug Movasin is issued in the form of tablets (7,5 or 15 mg), in packaging of 10 or 20 tablets, and also in the form of injection solution in oil (10 mg / 1 ml), in packaging of 3 or 5 ampoules on 1,5 ml.

Pharmacological action

Anesthetic, antiinflammatory, febrifugal.

Pharmacodynamics and pharmacokinetics

Movasin is non-steroidal anti-inflammatory drug (NPVS) which shows the anesthetizing, antiinflammatory and febrifugal efficiency.

Antiinflammatory effects of Movasin connect with a possibility of a meloksikam to brake enzymatic activity of TsOG-2 which is taking part in biosynthesis of prostaglandins in the place of an inflammation.

Also to meloksika, but to a lesser extent, influences TsOG-1 which promotes synthesis of the prostaglandin protecting mucous a gastrointestinal tract and participating in regulation of a renal blood-groove.

For injection introduction bioavailability of a meloksikam of nearly 100%. At intramuscular introduction of 5 mg of Movasin of Cmax it is observed through, about 60 minutes also equal 1,62 mkg/ml.

At oral administration it is soaked up from a gastrointestinal tract quite well, with bioavailability of 89%. In peroral doses of 7,5 and 15 mg, concentration of drug are proportional to doses. In 3-5 days equilibrium concentration are observed

Drug possesses good communication with plasma proteins, in particular with albumine (99%). Gets to synovial fluid, from 50% concentration from plasma. The volume of distribution is low, on average about 11 liters. Interindividual discrepancies, about 30-40%.

Meloksikam practically without the rest is metabolized in a liver, with allocation of 4 inactive metabolites. Basic of which — 5 -karboksimeloksikam (60%), received by oxidation of 5 -hydroxies-metilmeloksikama (an intermediate metabolite), in turn it is also excreted, but already in a smaller measure (9%).

According to the researches in vitro it is proved that the major role in this metabolic process is played by CYP2C9 isoenzyme, support function is carried out by CYP3A4 isoenzyme. Allocation of other two metabolites (16% and 4% respectively) takes place with peroxidase participation, with possibly varying activity.

Removal takes place with a stake and urine equally, generally in the form of metabolites. 5% are brought with a stake in not changed look. On average Т½ — 20 hours, plasma clearance — 8 ml/min.

Meloksikam in doses of 7,5-15 mg possesses linear pharmacokinetics.

Pathologies of a liver or moderately severe kidneys, significantly do not influence pharmacokinetics.

Indications to use

The indication to Movasin's use is carrying out a symptomatic treatment of such diseases as:


  • heart failure (dekompensirovanny);
  • the period after aortocoronary shunting;
  • combination a polypose mucous okolonosovy bosoms and a cover of a nose, bronchial asthma and intolerance of NPVS (including observed in the past);
  • painful conditions of intestines of an inflammatory etiology (illness Krone, ulcer colitis);
  • erosive and ulcer pathologies mucous gastrointestinal tract;
  • bleedings;
  • heavy pathologies of a liver;
  • HPN, without carrying out a dialysis (KK is less than 30 ml/min.), the progressing renal diseases (including the diagnosed hyperpotassemia);
  • pregnancy;
  • age till 12 years (for reception of tablets) and till 18 years (for carrying out in oil injections);
  • breastfeeding;
  • hypersensitivity to a meloksikam or other components of drug.

Movasin's tablets included lactose in this connection, do not recommend to people with deficit of lactase, intolerance of a galactose or glyukozo-galaktozny malabsorption this dosage form of drug.

With care

For the purpose of lowering of risk of possible undesirable manifestations from a gastrointestinal tract, it is necessary to use the smallest effective dosage of Movasin with the minimum reception on time.

Side effects


Alimentary system:

  • abdominal pains;
  • nausea;
  • meteorism;
  • vomiting;
  • eructation;
  • lock;
  • esophagitis;
  • diarrhea;
  • increase in activity of liver enzymes (passing);
  • hyperbilirubinemia;
  • gastritis;
  • gastroduodenal ulcer;
  • stomatitis;
  • gastrointestinal tract bleeding;
  • colitis;
  • perforation of a gastrointestinal tract;
  • hepatitis.

Cardiovascular system:

  • peripheral hypostases;
  • heartbeat;
  • increase of the ABP;
  • inflow.

Bodies of a hemopoiesis:

  • thrombocytopenia;
  • leukopenia;
  • anemia.


Respiratory system:

  • bronchospasm.

Urinary system:

  • increase of level of urea;
  • giperkreatininemiya;
  • renal failure in an acute form;
  • albuminuria, intersticial nephrite, hamaturia (with unspecified relationship of cause and effect).

Sense bodys:

  • vision disorders;
  • conjunctivitis.

Allergic manifestations:

Local reactions:

  • morbidity and/or puffiness in the place of an injection.

Application instruction of Movasin

Movasin's tablets, application instruction

Tablets are shown to be accepted orally (inside), during food, in a single daily dose of 7,5-15 mg.

For therapy of a pseudorheumatism recommend to appoint initially tablets on 15 mg. Being coordinated with further therapeutic effect a dosage it is possible to lower to 7,5 mg.

For therapy of an osteoarthrosis appoint tablets on 7,5 mg in the beginning. In case of absence or insufficiency of efficiency increase of a dosage to 15 mg is possible.

For therapy of an ankylosing spondylarthritis the dose of 15 mg is shown.

The most admissible daily dosage of Movasin no more than 15 mg. For the patients who are in risk group on relative contraindications, this dosage equals 7,5 mg.

Movasin's pricks, application instruction

In/in an injection are prohibited!

Pricks of Movasin in oil are shown only for the first 2-3 days. The subsequent treatment is continued by a peroral form of drug (tablet).

Depending on a disease and intensity of its current appoint injections on 7,5 or 15 mg, once in days.

Injections carry out deeply to a muscle.

The most admissible daily dosage of Movasin no more than 15 mg. For the patients who are in risk group on relative contraindications, this dosage equals 7,5 mg.


At overdose by Movasin observed disturbance of consciousness, vomiting, bleedings from a gastrointestinal tract, pains in epigastriums, nausea, acute insufficiency of kidneys and/or a liver, an asystolia, an apnoea.

The gastric lavage, internal reception of absorbent carbon (the next 60 minutes), further — a symptomatic treatment is shown. The hemodialysis, alkalization of urine and an artificial diuresis are ineffective, in connection with high extent of linkng of a meloksikam with plasma proteins.


The combined use with other NPVS increases a possibility of forming of bleedings of a gastrointestinal tract and erosive and ulcer complications.

Parallel reception with anti-hypertensive means can lead to lowering of effects of the last.

Joint therapy with drugs of lithium can cause its cumulation and as a result strengthening of its toxic action.

Co-administration with the Methotrexate increases probability of toxic impact on a hemopoiesis and development of a leukopenia and/or anemia.

Parallel use with Cyclosporine and diuretics increases risk of emergence of insufficiency of kidneys.

The combined reception with intrauterine contraceptives can lower their efficiency.

Joint treatment with anticoagulants (Warfarin, Tiklopidin, Heparin), and also with drugs of thrombolytic action (Fibrinolysin, Streptokinasa) increases risk of forming of bleedings.

One-time reception with Colestyraminum strengthens excretion of a meloksikam.

Joint appointment with SIOZS leads to increase of risk of developing of bleeding of a gastrointestinal tract.

Terms of sale

For Movasin's acquisition the recipe of the doctor is necessary.

Storage conditions

All forms of Movasin need to be stored in the dry and darkened room, at a temperature: for tablets – to 25 °C; for ampoules – to 30 °C.

Period of validity

Both forms of drug are suitable for the use for 3 years from the date of production.

Special instructions

With care patients in whose anamnesis there are references of a peptic ulcer, and also to the patients passing treatment with use of anticoagulants as this category of people is subject to the increased risk of emergence of erosive and ulcer complications of a gastrointestinal tract should apply Movasin.

Also, care at use of drug and control over function of kidneys is required from elderly patients, sick HSN with manifestations of a circulatory unefficiency, people with cirrhosis and the hypovolemia which developed after surgical interventions.

At a combination to diuretics it is necessary to accept the increased amount of liquid.

Patients with KK more than 30 ml/min. do not demand correction of the mode of dosing.

Movasin can mask symptomatology of diseases of the infectious nature.

Detection of allergic manifestations (itch of integuments, skin rash, photosensitization, the small tortoiseshell) demands the treatment termination.

Because of possible displays of dizziness, drowsiness, headaches it is necessary to be careful when driving transport and dangerous work.

Movasin's analogs

At sensitivity to a meloksikam can offer you its following analogs:


  • Movasin 7,5mg No. 20 tabletkisintez joint stock company
  • Movasin of 15 mg No. 20 tabletkisintez joint stock company
  • Movasin 10mg/ml solution for injections 1,5ml No. 5 ampulysintez joint stock company
  • Movasin 10mg/ml solution for injections 1,5ml No. 3 ampulysintez joint stock company
to show still
Section: For joints Anesthetics
in more detail

Education: Graduated from the Vinnytsia national medical university of N. I. Pirogov, pharmaceutical faculty, the higher pharmaceutical education – the specialty "Pharmacist".

Experience: Work in Koneks and Bios-Media pharmacy chains as "Druggist". Work as "Pharmacist" in Avicenna pharmacy chain of the city of Vinnytsia.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Movasin surely consult with the attending physician.